Investigation launched into Altria's claims on FDA status of nicotine pouch, affecting shareholders.

Levi & Korsinsky is investigating whether Altria Group misrepresented the FDA regulatory status of its on! PLUS nicotine pouch and the timing of FDA approvals for other applications. This follows a stock drop after Altria's Q2 2026 results and prior claims that on! PLUS was the only product authorized under the FDA pilot program. The investigation focuses on whether Altria's public statements were misleading about the FDA review process and timing, potentially violating securities laws. Shareholders who suffered losses are encouraged to submit information for evaluation.